GlassScriptPhysician profile
William W Huntley
NPI 1356440366
$1,928.18
in general payments reported to CMS, 2019-2025
27 companies · $34.18 in 2025
The $34.18 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $343 · 2021: $445 · 2022: $366 · 2023: $301 · 2024: $129 · 2025: $34.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $214.87 | 2019-2023 | |
| Amgen INC. | $203.78 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $185.57 | 2019-2023 | |
| Lilly USA, LLC | $173.06 | 2019-2025 | Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $108.18 | 2019-2024 | Austedo Xr, Austedo |
| Ucb, INC. | $98.96 | 2020-2022 | |
| Biogen, INC. | $83.64 | 2020-2023 | Tysabri |
| Eisai INC. | $77.78 | 2022-2024 | |
| Biohaven Pharmaceuticals, INC. | $77.02 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $69.33 | 2021-2023 | Andexxa |
| Sk Life Science, INC. | $67.95 | 2022 | |
| Pfizer INC. | $62.95 | 2023-2024 | |
| Life Molecular Imaging LTD | $58.72 | 2019-2023 | Neuraceq |
| Allergan, INC. | $55.69 | 2020 | |
| Supernus Pharmaceuticals, INC. | $46.59 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $43.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $38.27 | 2019 | |
| Neurocrine Biosciences, INC. | $37.00 | 2022-2023 | Ongentys, Ingrezza |
| Avanir Pharmaceuticals, INC. | $36.73 | 2021 | |
| Abbott Laboratories | $36.18 | 2023-2024 | Infinity |
| Lundbeck LLC | $34.45 | 2024-2025 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $26.98 | 2022 | |
| Acorda Therapeutics, INC | $26.96 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.75 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $16.29 | 2021 | |
| Corium, LLC | $15.98 | 2023 | Adlarity |
| Vertical Pharmaceuticals, LLC | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Huntley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.